Inflammatory uveitis is a difficult condition to treat. Recently, a new class of drugs obtained by a biologi- cal process and therefore defined as “biologics” has been successfully used in the treatment of immune- mediated rheumatic diseases. These drugs target dif- ferent pro-inflammatory cytokines including tumor necrosis factor-α, interleukin-1 and interleukin-6, or immune effector cells including B and T lymphocytes. Their use has been then extended to different forms of uveitis resistant to standard therapy in small un- controlled trials, with general and unexpected effi- cacy. The present review analyzes the literature on treatment of uveitis with the biologics currently available for the treatment of inflammatory rheu- matic diseases. We used PubMed search engine as the main source of information. Among the papers in- cluded in the reference list, a particular emphasis was given on articles published during the last 5 years.
Inflammatory uveitis is a difficult condition to treat. Recently, a new class of drugs obtained by a biologi- cal process and therefore defined as “biologics” has been successfully used in the treatment of immune- mediated rheumatic diseases. These drugs target dif- ferent pro-inflammatory cytokines including tumor necrosis factor-α, interleukin-1 and interleukin-6, or immune effector cells including B and T lymphocytes. Their use has been then extended to different forms of uveitis resistant to standard therapy in small un- controlled trials, with general and unexpected effi- cacy. The present review analyzes the literature on treatment of uveitis with the biologics currently available for the treatment of inflammatory rheu- matic diseases. We used PubMed search engine as the main source of information. Among the papers in- cluded in the reference list, a particular emphasis was given on articles published during the last 5 years.
Biological agents in the treatment of uveitis / Paroli, Maria Pia; Alessandro, Abbouda; Abicca, Irene; Alfredo, Sapia; Paroli, Marino. - In: ADVANCES IN BIOSCIENCE AND BIOTECHNOLOGY. - ISSN 2156-8456. - STAMPA. - 04:08(2013), pp. 64-72. [10.4236/abb.2013.48a2009]
Biological agents in the treatment of uveitis
PAROLI, Maria Pia;ABICCA, IRENE;PAROLI, Marino
2013
Abstract
Inflammatory uveitis is a difficult condition to treat. Recently, a new class of drugs obtained by a biologi- cal process and therefore defined as “biologics” has been successfully used in the treatment of immune- mediated rheumatic diseases. These drugs target dif- ferent pro-inflammatory cytokines including tumor necrosis factor-α, interleukin-1 and interleukin-6, or immune effector cells including B and T lymphocytes. Their use has been then extended to different forms of uveitis resistant to standard therapy in small un- controlled trials, with general and unexpected effi- cacy. The present review analyzes the literature on treatment of uveitis with the biologics currently available for the treatment of inflammatory rheu- matic diseases. We used PubMed search engine as the main source of information. Among the papers in- cluded in the reference list, a particular emphasis was given on articles published during the last 5 years.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
